CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 1
2016 Pharmacy Education Series
February 17, 2016CHS F l M t P A l A l d B dCHS Formulary Management Process – Approval, Appeals, and Beyond
Featured Speaker:Heather Ann Wier Weese, PharmD, BCPSManager, Formulary and Pharmacy StandardsCHS Professional Services Corporation
1
Submission of an online evaluation is the only way to obtain CE credit
Online Evaluation, Self-Assessmentand CE Credit
Submission of an online evaluation is the only way to obtain CE credit for this webinar
Go to www.ProCE.com/CHSRx Webinar attendees will also receive an email with a direct link to the
web page Print your CE statement of completion online
– Credit for live or enduring only
Deadline: March 18, 2016( l bl h )
2
CPE Monitor (applicable to pharmacists)– CE information automatically uploaded to NABP/CPE Monitor within 1 to 2
weeks of the completion of the self‐assessment and evaluation
Event Code
Code will be provided at the end of today’s activity
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 2
How to Ask a Question
Locate menu bar on your computer desktop Click No!
Click orange arrow button
Menu box will open
Type question into question box
Click Send
Do not close menu box
– This will disconnect you from the Webcast
Please submit questions throughout presentation
Enter question
Click Send
3
Accessing PDF Handout
Click the hyperlink that is located directly above the No!located directly above the question box
Do not close menu box
– This will disconnect you
from the Webcast
Close other applications Clickhyperlinkhyperlink
4
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 3
2016 Pharmacy Education SeriesFebruary 17, 2016
CHS Formulary Management Process – Approval, Appeals, and Beyond
Featured Speaker:Heather Ann Wier Weese, PharmD, BCPSManager, Formulary and Pharmacy StandardsCHS Professional Services Corporation
5
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Heather Weese has no relevant commercial and/or financial relationships to disclose.
Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.
CE Activity Information & Accreditation
ProCE, Inc. (Pharmacist CE)
– 2.0 contact hours
Funding:This activity is self‐funded through CHSPSC
6
This activity is self funded through CHSPSC.
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 4
Community Health SystemsCommunity Health SystemsCommunity Health Systems Community Health Systems Formulary Management Process Formulary Management Process ––Approvals, Appeals, and BeyondApprovals, Appeals, and Beyond
Heather Weese, Pharm.D.
Director, Pharmacy Operations and Informatics
7
Disclosure
I do not have (nor does any immediate family member have) an interest in or affiliation with any organizationhave) an interest in or affiliation with any organization offering financial support or grant monies other than reasonable honoraria and expenses for this continuing education activity. In addition, I have received no financial support of any kind from the manufacturer, developer or distributor of a product / device that will p f p /be discussed during my presentation.
8
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 5
Learning Objectives
At the conclusion of this presentation, participants will be able to:• Describe the formulary status designation process for new drug requests and new FDA drug approvals
• Define the appropriate mechanism for submitting an appeal for a non‐formulary medication
• Identify and respond to commonly asked questions concerning the formulary process
• Explain the rationale behind therapeutic interchange and how it applies to our organization
• Evaluate scenarios for requests and appeals for appropriate escalation
9
Goals of this Presentation
Deliverables:
• Enhance understanding of the formulary, the rationale behind the formulary, and commonly asked questions
• Review important documents, their location, and how to use themand how to use them
• Provide examples of situations and how to apply knowledge gained today
10
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 6
Presentation Outline
• Rationale and argument for formulary t d di tistandardization
• Formulary structure
• Appeals Process
• Formulary Tools and Helpful Materials
11
RATIONALE FOR FORMULARY STANDARDIZATION – WHY STANDARDIZE?
12
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 7
What is a Formulary?
• A continually updated list of medications and related information, representing the clinical judgment of pharmacists, physicians, and other experts in the diagnosis and treatment of disease and promotion of health
• A formulary includes, but is not limited to, a list of medications and medication‐associated products or devices, medication‐use policies, important ancillary drug information, decision‐support tools, anddrug information, decision support tools, and organizational guidelines
‐ ASHP Statement on the Pharmacy and Therapeutics Committee and the Formulary System
13
Why Have a Formulary?
• Governance
– Safety, cost‐effectiveness
• Internal processes/policies
• Compliance
• Billing
• Informatics
Boucher BA. Formulary decisions: then and now. Pharmacotherapy 2010;30:35S‐41S14
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 8
Why Have a Organizational Standard Formulary?
• Centralized platforms
– Electronic health record, smart infusion pumps
• Centralized processes
– Billing, order set development
• Centralized standards
C t ti f i t th ti– Concentrations, frequencies, routes, therapeutic interchange, etc.
15
CHS Formulary History
• 2011 – Review process initiated
• 2012 – Obtained buy‐in from CHSPSC leadership
• 2013 – Formulary policy developed; integration time line to 2015 developed
• 2014 – Formulary rollout initiated
• 2015 – Formulary integration process completed2015 Formulary integration process completed
• 2016 – Maintenance phase
16
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 9
Are other Organizations Doing This?
• YES!
17
What Benefits are We Seeing?
• Centralized standardization
• Improved formulary adherence
• Feedback mechanism
18
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 10
Why Therapeutic Interchange?
• Centralized platforms
• Drug cost optimization
• Minimization of therapeutic duplication
• Promotion of best practices and standards
• Contract optimization
Gray T et al. ACCP Position Statement: Guidelines for therapeutic interchange – 2004. Pharmacotherapy 2005;25(11):1666‐1680. 19
COMMUNITY HEALTH SYSTEMS FORMULARY MANAGEMENT SYSTEM
20
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 11
RX08‐04 Formulary System Policy
Establishes:
• Enterprise‐wide formulary and formulary process
– Maintenance process
– Approval process
– Appeal processAppeal process
• Formulary Status Categories
21
08‐03‐H Obtaining Non‐Formulary Drugs
• Establishes:
– Process for obtaining non‐formulary drugs
• Review by a pharmacist
• Determination that formulary drug is not appropriate for patient
22
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 12
Recommending Bodies
• Clinical Pharmacy Council– A standing committee representing a clinical voice to assistA standing committee representing a clinical voice to assist CHS in implementing best practices in pharmacotherapy, including clinical initiative programs, pharmacy residency programs, and clinical interventional programs
– Made up entirely of pharmacists
• Formulary Management Committee– A collaborative group charged with conductingA collaborative group charged with conducting comprehensive reviews and analyses of medications for the purpose of making formulary recommendations to the Medication Management Committee
– Made up of both physicians and pharmacists
23
Approving Bodies
• Medication Management Committee
– A standing committee tasked with oversight of pharmacy operations and formulary decisions
• Made up of representatives form Corporate Leadership
24
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 13
Formulary Requests and Approval
• No local hospital P&T Committee may establish a medication as formulary withoutestablish a medication as formulary without prior addition to the CHSPSC Master Drug Formulary
• Requests may be made by requesting a New Drug Request form from Joanne Smyth (Joanne Smyth@chs net)([email protected])– This is noted on each week’s Weekly Formulary Update Newsletter
25
New Drug Approvals by the FDA
• Newly marketed medications default to C t B d i i thi t t til thCategory B and remain in this status until the medication is requested, reviewed, and admitted to the formulary
• New drugs approved by the FDA are announced on the Weekly Formulary Update y y pNewsletter
26
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 14
Affiliate Formulary Management
27
How to Initiate a Request
Request may come from a physician or other
ib t DOP
Request may come from a physician or other
ib t DOP
Use Micromedex Formulary Advisor to D t i F l
Use Micromedex Formulary Advisor to D t i F l
Appeals are a separate process that we will review later in the
Appeals are a separate process that we will review later in theprescriber to DOPprescriber to DOP Determine Formulary
StatusDetermine Formulary
Status
review later in the presentation
review later in the presentation
Please consider closely your own opinion of the
request
Please consider closely your own opinion of the
request
Remember that DOPs have the ability to deny requests for additions of
medications
Remember that DOPs have the ability to deny requests for additions of
medications
Send email to [email protected]. If you forget this, it appears weekly on the Weekly Formulary Update
Send email to [email protected]. If you forget this, it appears weekly on the Weekly Formulary Update
28
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 15
Formulary Status Categories
• Category A: Full Formulary Status– Category A1: Therapeutic Equivalents: agents so similar in efficacy and safety
that they can be interchanged without any risk to the patient or compromisethat they can be interchanged without any risk to the patient or compromise in efficacy. Equivalents currently not included on the formulary would fall in non‐formulary category C
– Category A2: Class Representatives: agents with similar efficacy and safety, but some differences preclude auto‐substitution. Prior therapy would be continued, but orders for initiation of therapy would be directed to the formulary agent. Other agents considered acceptable to represent the class but not currently on the formulary would fall in category B
– Restricted Use: Despite formulary status, restrictions may be imposed on use of medications. Criteria outside restrictions, would follow non‐formulary request procedures (Policy 08‐03‐H)request procedures (Policy 08‐03‐H)
• Take home message(s):– Category A products are the only products eligible for addition to local
hospital formularies– Hospitals may choose to exclude some Category A products from their local
formulary if they are unneeded
29
Formulary Status Categories
• Category B: Non‐Formulary:– These agents are not routinely available for use or stockedThese agents are not routinely available for use or stocked in the pharmacy. In certain circumstances, these agents may be ordered for specific patient needs in accordance with Policy 08‐03‐H. Non‐formulary class representatives would fall into this category, unless otherwise stated
• Take home message(s):– Category B products may not be considered for addition to local hospital formulary
– Category B products should not be presented to individual hospital P&T committees for formulary consideration
30
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 16
Formulary Status Categories
• Category C: Non‐Formulary; Not‐AvailableThese agents have specifically been singled out for no– These agents have specifically been singled out for no patient care use within CHS affiliates. These will not be ordered nor stocked at affiliate facilities. These would typically include medications with high‐risk or pose safety concerns, but also include medications for which therapeutic equivalents exist. Alternatives will be designated when an agent is placed in this g g pcategory. Rare exceptions to this must be approved through the affiliate resolution process, documented in the quarterly action plans, and reviewed with the Regional Pharmacy Directors, no less than quarterly.
31
Patient Case
• Mrs. M is a 73 year old female patient who is b i d itt d t h it l Whilbeing admitted to your hospital. While processing her orders you notice that the physician has ordered a Category B drug for Mrs. M. How do you proceed?
32
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 17
Patient Case ‐ Answer
• Follow the process outlined in Policy 08‐03‐H– As the pharmacist processing orders for Mrs. M, you p p g , yshould reach out to the physician and determine why he or she ordered a Category B medication for Mrs. M. If, after discussion with the prescriber you and the prescriber are able to determine that an alternative formulary agent is not appropriate and that the therapy is necessary for the patient admission then the Category B medication may be obtained
• Take home message(s):• Take home message(s):– Hospital pharmacists may determine the appropriateness of a Category B medication on their own and justify it using their clinical judgment
33
How are Category Statuses Assigned?
34
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 18
How are Category Statuses Assigned?
35
Formulary Category Status Assignment Example
• One of your cardiologists is interested in prescribing a new antihypertensive medicationprescribing a new antihypertensive medication that has not been used at your facility. After checking Formulary Advisor to determine the formulary status of the medication, you learn that it is a Category B medication. You agree that there is merit to this medication becoming a Category A product since there are no therapeutically equivalent medications on formulary. What do you do?
36
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 19
Formulary Category Status Assignment Example
• Step 1 – email Joanne Smyth (J S th@ h t) t bt i([email protected]) to obtain a new drug request form
• Who is responsible for filling out the request form?
37
Formulary Category Status Assignment Example
– Affiliate Pharmacy Directors
– CHSPSC Pharmacists
– Physicians requesting medications for addition
• As described above proposals should beAs described above, proposals should be submitted to the CHSPSC Clinical Director of Pharmacy or designee– Formulary manager
38
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 20
Formulary Category Status Assignment Example
• Upon receipt of the new drug request form, the Formulary Manager conducts and independent review of the antihypertensive medication– Review includes:
• Monograph• Review of primary literature• Review of similar medications• Discussion with major Formulary Management Committee stakeholderC t i• Cost comparison
– Formulary Manager creates initial recommendation of Category A for medication given that no other therapeutic equivalents exist
39
Formulary Category Status Assignment Example
• Formulary Manager presents initial d ti t CHSPSC Phrecommendation to CHSPSC Pharmacy
Leadership
– CHSPSC Pharmacy Leadership agrees with recommendation
• Formulary Manager presents y g precommendation to Clinical Pharmacy Council
– May be presented at a live meeting or over email (about a week turn around time)
40
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 21
Formulary Category Status Assignment Example
• Clinical Pharmacy Council agree with recommendation but feel that it would berecommendation, but feel that it would be justified to add in an additional stipulation that this antihypertensive should be used as second‐line therapy– Restriction
• Formulary Manager adds the restriction• Formulary Manager adds the restriction proposed by the Clinical Pharmacy Council to the monograph
41
Formulary Category Status Assignment Example
• Formulary Manager presents revised monograph and recommendation to the Formulary Management Committee– May be presented at a live meeting or over email (about a week turn around time)
• Formulary Management Committee agrees that this antihypertensive should be added to formulary and also agrees with the Clinical Pharmacy Council that it should have a restriction for second line therapy useshould have a restriction for second line therapy use only or for patients that have come in on the therapy from home– Monograph updated to add additional restriction criteria
42
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 22
Formulary Category Status Assignment Example
• Formulary Manager updates Weekly Formulary Update to reflect approval statusUpdate to reflect approval status
• Open comment period commences
• Recommendation presented to Medication Management Committee– During regularly scheduled quarterly meetings
• Decision communicated through Weekly• Decision communicated through Weekly Formulary Update Newsletter
43
Formulary Assignment Communication
44
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 23
Notes About Medication Proposals
• Medications that are not FDA‐approved or h b i d ithi th t illhave been reviewed within the past year will not be considered
– May be reviewed through appeals process for medications reviewed within the last year only
45
What are Appeals and How to they Work?
• Appeals happen when:
– A hospital physician disagrees with a formulary Category Status
– A hospital physician disagrees with a clinical i iti tiinitiative
46
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 24
Appeal Basics
• Appeals should come from the hospital through the Director of Pharmacythrough the Director of Pharmacy
• Essential elements– Letter from physician
• Explaining rationale
• Defending recommendation
Supplemental literature– Supplemental literature
• Appeal materials should be forwarded to the Formulary Manager
47
Appeal ‐ Example
• Cangrelor (KengrealTM) was reviewed in July 20152015
• Communication regarding new request received in October 2015– Recommended by CHSPSC Pharmacy Leadership to come through appeals process
A l l tt i d i J 2016• Appeal letter received in January 2016– Presented article that was reviewed in original monograph
48
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 25
Appeal ‐ Example
• Appeal reviewed by Formulary Management Committee in January 2016Committee in January 2016– Letter
– Evidence
– Previous monograph• Decision‐making rationale
• Literature included in review
– Input of interventional cardiologist on committee
• Appeal was denied citing lack of sufficient additional evidence
49
What is Special about the Maintenance Phase?
• Formulary perfection
• Review of new and requested medications is ongoing
• Appeals
50
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 26
Where is My Voice in the Process?
51
Where do Items Enter the Formulary Process?
• Three main places
– Represented by yellow hexagons
52
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 27
Examples of Items Entering the Formulary Process
• New drug requested by a h i i t th h it lphysician at the hospital
level
• New drug approved by the FDA
• Appeal to long‐standingAppeal to long‐standing clinical initiative
53
How Does the Formulary Process Relate to Clinical Initiatives?
• Clinical Initiatives are all reviewed and d d b th F l M tendorsed by the Formulary Management
Committee
– Some are also reviewed by the Clinical Pharmacy Council
• Appeals for Clinical Initiatives are reviewed by pp ythe Formulary Management Committee
54
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 28
IMPORTANT FORMULARY‐RELATED RESOURCES
55
Formulary Policy/Obtaining Non‐Formulary Drugs Policy
56
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 29
Formulary Policy/Obtaining Non‐Formulary Drugs Policy
57
Notes Regarding Communication
58
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 30
Formulary Flow Map
59
Formulary Flow Map ‐ Key
• Yellow hexagon – point of entry into formulary processformulary process
• Green square – internal, person‐to‐person or person‐to‐committee communication
• Red diamond – decision• Blue parallelegram – decision flow
h tchart• Purple oval – widespread communication to large group of people
60
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 31
Micromedex Formulary Advisor
61
Micromedex – Logging In
• Username: Commhealth
• Password: Commhealth
62
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 32
Formulary Advisor ‐ Site
63
Formulary Advisor ‐ Site
64
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 33
Formulary Advisor ‐ Corporate
• Category assignment of all medications h d b t i t thpurchased between one year prior to the
formulary reset and present
• Unable to re‐send an upload at present
– Future
• Any file downloaded from here does not• Any file downloaded from here does not contain NDCs
65
Formulary Advisor ‐ Affiliate
• Each hospital is responsible for maintaining a i f F l Ad i ifi f th iversion of Formulary Advisor specific for their
own formulary
• Autonomy to be more restrictive
• Enter information unique to your hospital
• Display accurate information to your• Display accurate information to your prescribers
66
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 34
Formulary Monographs/Formulary Resources
67
Formulary Monograph Organization
68
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 35
Formulary Monographs/Formulary Resources
69
Formulary Monograph Layout
70
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 36
Formulary Monograph Layout
71
Formulary Monograph Layout
72
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 37
Formulary Study Review Layout
73
Clinical Initiative Toolkits
74
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 38
Clinical Initiative Toolkits ‐Website
75
Clinical Initiative Toolkits ‐Website
Summary of Clinical Initiative
Documents section:ToolkitFAQ
Medication Use Evaluation (if applicable)Key Articles
76
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 39
Clinical Initiative Toolkits ‐ Format
• New format going f dforward
– Title
– Approval Dates
– Version Information
– Hyperlinked Table ofHyperlinked Table of Contents
77
Weekly Formulary Update Newsletter
• Weekly Newsletter containing important formulary‐related informationformulary related information
• Main sections:– This Week’s News– Formulary Request Tracker– Clinical Pharmacy Website Additions– Therapeutic Interchanges GuideF l St t f N FDA R i d D– Formulary Status of New FDA‐Reviewed Drugs
• Yellow = New this week• Green = Anticipated Date
78
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 40
This Week’s News
• Upcoming clinical initiatives• Outsourced compounding products informationp g p• Reminders• Open comment periods• Formulary changes in status
79
Formulary Tracker
• Tracks medications through the formulary process
• Use your voice!
80
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 41
Website Updates
• Important additions to the Clinical or F l R th PhFormulary Resources pages on the Pharmacy Intranet
81
Therapeutic Interchange Guide Updates
82
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 42
FDA Drug Approvals
83
How to Use the Weekly Formulary Update
• Link to CHS Pharmacy Leadership
• Start with one week and stay up‐to‐date with yellow information
• Identify key information impacting your hospital
Share with others!– Share with others!
84
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 43
Speaking to Your P&T/Physicians about the Corporate Formulary
• Importance of standardization
– Ordersets
– Electronic health record
– Safety
– Waste reduction
• Group purchasing organizationGroup purchasing organization
• Big picture
85
Community Health SystemsCommunity Health Systems
Questions?Questions?
Community Health Systems Community Health Systems Formulary Management Process Formulary Management Process ––Approvals, Appeals, and BeyondApprovals, Appeals, and Beyond
Heather Weese, Pharm.D.
Director, Pharmacy Operations and Informatics
86
CHS Formulary Management Process – Approval, Appeals, and BeyondCHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 44
U d t C tU d t C t PhPhUpdate on Current Update on Current Pharmacy Pharmacy Initiatives and StrategiesInitiatives and Strategies
88
Robert Fink, Pharm.D., M.B.A., FASHP, FACHE, BCNSP, BCPS
Chief Pharmacy Executive
Community Health Systems
89